Hypoallergenic and Anti-inflammatory Feeds in Malawian Children With Severe Acute Malnutrition (SAM)

NCT ID: NCT02639416

Last Updated: 2021-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-01

Study Completion Date

2017-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Children with complicated severe acute malnutrition (SAM), such as inability to take adequate feeds, infection and diarrhoea, require in-patient management. Despite following a well-established World Health Organisation (WHO) protocol, outcomes are poor. Case fatality often exceeds 20%. Amongst survivors discharged home, many subsequently die, have long-term poor growth or recurrence of SAM.

It has long been recognized that children with SAM have intestinal inflammation and that this persists despite management according to WHO guidelines. The inflammation is thought to result from increased exposure to microbial pathogens in the gut in areas with poor sanitation. The damaged lining of the intestine impairs food digestion and absorption, likely allows gut bacteria to enter the blood stream to cause sepsis and also exposes the gut immune cells to microbial and food antigens causing the inflammation to persist. Failure to treat the intestinal inflammation is likely to contribute to the poor response to treatment and poor long-term outcomes in many children with SAM.

The intestinal inflammation seen in SAM is very similar to that which occurs in food intolerance (e.g. intolerance to cow's milk protein) and inflammatory bowel disease. In these conditions, the inflammation is treated very effectively with hypoallergenic ("elemental") and anti-inflammatory ("polymeric") formulas. These are nutritionally complete feeds that have a similar composition to the feeds used for nutritional rehabilitation in SAM.

We aim to undertake a pilot study to see if an elemental and/or polymeric formula are tolerated by children with SAM and help to reduce intestinal inflammation. We also aim to learn more about the intestinal inflammation in general that occurs in SAM by observing carefully the effect of these specific formulae and to do in-depth metabolic analyses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will study children admitted to the Moyo ward at the Queen Elizabeth Central Hospital, Blantyre, Malawi with complicated SAM. Following informed consent, children will be recruited once they have completed the initial stabilisation phase of management and enter the transition phase to nutritional rehabilitation. They will be randomly allocated to one of 3 arms, either 1) standard feeds (F-100 and/or ready-to-use therapeutic feeds), 2) a polymeric therapeutic formula or 3) an elemental therapeutic formula. The alternative feeds will be supplemented with micronutrients to be equivalent in composition to F-100. All children will remain admitted to the ward for 2 weeks and receive exclusively the allocated formula. All other aspects of the management of SAM will follow current practice based on WHO guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Malnutrition Enteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard management

Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days

Group Type ACTIVE_COMPARATOR

Standard management

Intervention Type OTHER

Standard management with F-100 and/or RUTF

Polymeric formula

Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days

Group Type EXPERIMENTAL

Polymeric formula

Intervention Type DIETARY_SUPPLEMENT

Polymeric formulae are recommended in the management of inflammatory bowel disease in children

Elemental formula

Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days

Group Type EXPERIMENTAL

Elemental formula

Intervention Type DIETARY_SUPPLEMENT

Elemental formulae are recommended in cow's milk and other food intolerances in children.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polymeric formula

Polymeric formulae are recommended in the management of inflammatory bowel disease in children

Intervention Type DIETARY_SUPPLEMENT

Elemental formula

Elemental formulae are recommended in cow's milk and other food intolerances in children.

Intervention Type DIETARY_SUPPLEMENT

Standard management

Standard management with F-100 and/or RUTF

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6-23 months
* SAM diagnosed according to WHO criteria: (Weight-for-height z score \<-3 and/or mid-upper arm circumference \<11.5 cms and/or nutritional oedema)
* Admitted to hospital because of SAM with medical complications or fails an appetite test
* Completed stabilization phase and entering the second phase in refeeding; the transition Phase
* Willing to stay on the ward for 2 weeks after the stabilization phase (travel expenses will be provided)

Exclusion Criteria

* Specific cause of malnutrition (e.g. cerebral palsy, other organ disease)
* Sibling admitted with SAM at the same time
* Unwilling to stay on ward for at least 2 weeks
* Declined to give consent
* Participating in another study
Minimum Eligible Age

6 Months

Maximum Eligible Age

23 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Toronto

OTHER

Sponsor Role collaborator

Kamuzu University of Health Sciences

OTHER

Sponsor Role collaborator

Queen Elizabeth Central Hospital, Blantyre, Malawi

UNKNOWN

Sponsor Role collaborator

Liverpool School of Tropical Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen J Allen, MD

Role: PRINCIPAL_INVESTIGATOR

Liverpool School of Tropical Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Moyo ward, Department of Paediatrics, Queen Elizabeth Central Hospital

Blantyre, Southern Region, Malawi

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malawi

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15.048

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Choline to Prevent SAM in Children With MAM
NCT06214897 ACTIVE_NOT_RECRUITING NA
Whey Permeate Study
NCT01790048 COMPLETED NA